MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

Phase 1
Recruiting
Conditions
Pain
Appetite Loss
Abuse, Drug
Interventions
Drug: High CBG
Drug: Low CBG
Drug: Placebo
First Posted Date
2021-04-26
Last Posted Date
2024-07-25
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
20
Registration Number
NCT04859296
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

Phase 2
Recruiting
Conditions
Cannabis Use
HIV
Interventions
First Posted Date
2021-03-16
Last Posted Date
2023-10-04
Lead Sponsor
University of California, San Diego
Target Recruit Count
40
Registration Number
NCT04800159
Locations
🇺🇸

Ucsd Hnrp-Cmcr, San Diego, California, United States

The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products

Phase 1
Completed
Conditions
Cannabis
Drug Effect
Interventions
Drug: Placebo
First Posted Date
2021-02-05
Last Posted Date
2023-03-10
Lead Sponsor
Johns Hopkins University
Target Recruit Count
47
Registration Number
NCT04741477
Locations
🇺🇸

Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Dronabinol in Total Knee Arthroplasty (TKA)

Phase 4
Completed
Conditions
Opioid Use
Total Knee Arthroplasty
Interventions
Other: Placebo oral tablet
First Posted Date
2021-02-02
Last Posted Date
2025-01-24
Lead Sponsor
Hospital for Special Surgery, New York
Target Recruit Count
114
Registration Number
NCT04734080
Locations
🇺🇸

Hospital for Special Surgery, New York, New York, United States

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

Phase 1
Recruiting
Conditions
Cannabis
Interventions
Drug: Placebo
First Posted Date
2021-01-11
Last Posted Date
2025-03-06
Lead Sponsor
Yale University
Target Recruit Count
100
Registration Number
NCT04704271
Locations
🇺🇸

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

🇺🇸

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study

Not Applicable
Completed
Conditions
Schizophrenia
Cannabis Use
Interventions
First Posted Date
2020-10-28
Last Posted Date
2023-08-18
Lead Sponsor
King's College London
Target Recruit Count
36
Registration Number
NCT04605393
Locations
🇬🇧

South London and Maudsley NHS Foundation Trust, London, United Kingdom

The Effect of Dronabinol on Ocular Hemodynamics in Patients With Primary Open Angle Glaucoma

Phase 2
Completed
Conditions
Retinal Blood Flow
Interventions
First Posted Date
2020-10-22
Last Posted Date
2025-05-16
Lead Sponsor
Medical University of Vienna
Target Recruit Count
51
Registration Number
NCT04596826
Locations
🇦🇹

Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria

Reward and Drug Effects on Mood and Brain Response

Early Phase 1
Completed
Conditions
Cannabis Use
Healthy
Interventions
Drug: Placebo oral capsule
First Posted Date
2020-08-13
Last Posted Date
2025-05-21
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
141
Registration Number
NCT04512365
Locations
🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

Analgesic and Subjective Effects of Terpenes

Phase 1
Recruiting
Conditions
Pain
Abuse, Drug
Interventions
First Posted Date
2020-06-30
Last Posted Date
2024-12-20
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
45
Registration Number
NCT04451863
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

Phase 4
Active, not recruiting
Conditions
Pregnancy Related
Cannabis Use
Interventions
First Posted Date
2020-05-05
Last Posted Date
2024-08-19
Lead Sponsor
University of Washington
Target Recruit Count
12
Registration Number
NCT04374773
Locations
🇺🇸

Nina Isoherranen, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath